Trial
NCT05218096
Study of ALXN2050 in Adult Participants With Generalized Myasthenia Gravis
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Alexion Pharmaceuticals, Inc.
Collaborators
—
Condition
Generalized Myasthenia Gravis
Intervention
ALXN2050
Why stopped
Sponsor decision
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-01-09